RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $14

Benzinga · 1d ago
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $14.